Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

Journal of Human Hypertension

Volumn 18, Issue 10, 2004, Pages 687-691

  Mugellini, A ^a   Preti, P ^a   Zoppi, A ^a   Corradi, L ^a   Fogari, E ^a   Derosa, G ^a   Fogari, R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Delapril manidipine; Diabetes; Fibrinolysis; Irbesartan hydrochlorothiazide

Indexed keywords

DELAPRIL; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN; MANIDIPINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYSIS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRAZOLES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 5644243400     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001726     Document Type: Article

References (43)

1. Chobanion AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
3. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of microvascular and macrovascular complications in type II diabetes: UKPDS 38. Br Med J 1998; 317 703-713.
4. Hansson L et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351: 1755-1762.
5. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153.
6. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S-45S.
7. Folsom AR et al. Prospective studies of markers of hemostatic function with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Circulation 1999; 100: 736-742.
8. Held C et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study, the angina prognosis study in Stockholm Atherosclerosis 2000; 148: 179-188.
9. Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator inhibitor antigen in essential hypertension: a population based study in Sweden. J Hypertens 1997; 15: 349-356.
10. Poli KA et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-269.
11. McGill JB et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109.
12. Meigs JB et al. Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offsprings Study. JAMA 2000; 283: 221-228.
13. Lottermoser K et al. Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 1998; 11: 378-384.
14. Chohan IS, Singh J, Vermylen J, Verstraete M. Effect of furosemide on plasma fibrinolytic activity and urokinase excretion. Exp Haemat 1977; 5: 153-157.
15. Pedersen OD et al. Regulation of tissue-type plasminogen activator inhibitor type-1 in patients with ischemic heart disease: possible unfavourable effect of diuretics. Coronary Artery Disease 1994; 5: 617-623.
16. Winther K. The effect of beta-blockade on platelet function and fibrinolytic activity. J Cariovasc Pharmacol 1987; 10 Suppl 2): S94-S98.
17. Wright RA et al. The long-term effect of metoprolol and epanolol on tissue type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischemic heart disease. Eur J Clin Pharmacol 1994; 46: 279-282.
18. Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 1991; 4: 168S-171S.
19. Gleerup G et al. Does antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991; 18(Suppl 3): S34-S36.
20. Wright RA et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
21. Vaughan DE et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442-447.
22. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin emzyme inhibition and angiotensin II type I receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-290.
23. Fogari R et al. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type II diabetic patiens. J Hypertens 1999; 17(Suppl 3): P1.134 S58 (Abstract).
24. Fogari R et al. Differential effects of ACE-inhibition and Angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive post-menopausal women. Am J Hypertens 2001; 14: 921-926.
25. Seljeflot I et al. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304.
26. Oikawa T et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the antifibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-172.
27. Erdem Y et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071-1076.
28. Razzetti A, Acerbi D. Pharmacokinetic and pharmacological properties of delapril, a lipophilic, non sulphydril ACE inhibitor. Am J Cardiol 1995; 75: 7F-12F.
29. Cheer SM, McClellan K. Manidipine. Drugs 2001; 61 1777-1799.
30. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 281: 1039-1057.
31. Kluft C et al. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fasting acting inhibitor (PAI-1). Thromb Haemost 1989; 59: 329-332.
32. Randy M, Sundell IB, Nilssan TK. Blood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917-922.
33. Eriksson E, Tengborn L, Risberg B. The effect of various anticoagulant/antiplatel et mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 1989; 61: 511-516.
34. Wiman B, Mellbring G, Randy M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288.
35. Chmielewska J, Randy M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.
36. Ridker PM et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-1973.
37. Vaughan DE, Lazos A, Tong K. Angiotensin II regulates the expression of plasminofer activator inhibitor 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
38. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-525.
39. Juhan-Vague I, Alessi MC. Pai-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
40. Fogari R et al. Ace-inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-620.
41. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapaptide Angiotensin IV. J Clin Invest 1995; 96: 2515-2520.
42. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579-584.
43. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073.